| Cancer therapy shapes the fitness landscape of clonal hematopoiesis KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ... Nature genetics 52 (11), 1219-1226, 2020 | 449 | 2020 |
| TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? KH Stopsack, LA Mucci, ES Antonarakis, PS Nelson, PW Kantoff Cancer discovery 10 (6), 779-782, 2020 | 398* | 2020 |
| Blastocystis sp. subtype 2 detection during recurrence of gastrointestinal and urticarial symptoms C Vogelberg, CR Stensvold, S Monecke, A Ditzen, K Stopsack, ... Parasitology international 59 (3), 469-471, 2010 | 149 | 2010 |
| Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer KH Stopsack, S Nandakumar, AG Wibmer, S Haywood, ES Weg, ... Clinical Cancer Research 26 (13), 3230-3238, 2020 | 126 | 2020 |
| Aneuploidy drives lethal progression in prostate cancer KH Stopsack, CA Whittaker, TA Gerke, M Loda, PW Kantoff, LA Mucci, ... Proceedings of the National Academy of Sciences 116 (23), 11390-11395, 2019 | 116 | 2019 |
| Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations JM Mota, E Barnett, JT Nauseef, B Nguyen, KH Stopsack, A Wibmer, ... JCO precision oncology 4, 355-366, 2020 | 115 | 2020 |
| Cholesterol uptake and regulation in high-grade and lethal prostate cancers KH Stopsack, TA Gerke, O Andrén, SO Andersson, EL Giovannucci, ... Carcinogenesis 38 (8), 806-811, 2017 | 115 | 2017 |
| Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression G Chakraborty, J Armenia, YZ Mazzu, S Nandakumar, KH Stopsack, ... Clinical Cancer Research 26 (8), 2047-2064, 2020 | 95 | 2020 |
| Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics B Nguyen, JM Mota, S Nandakumar, KH Stopsack, E Weg, D Rathkopf, ... European urology 78 (5), 671-679, 2020 | 84 | 2020 |
| Metformin and prostate cancer mortality: a meta-analysis KH Stopsack, DR Ziehr, JR Rider, EL Giovannucci Cancer causes & control 27, 105-113, 2016 | 81 | 2016 |
| Cholesterol metabolism and prostate cancer lethality KH Stopsack, TA Gerke, JA Sinnott, KL Penney, S Tyekucheva, HD Sesso, ... Cancer research 76 (16), 4785-4790, 2016 | 70 | 2016 |
| Genetic and epigenetic determinants of aggressiveness in cribriform carcinoma of the prostate H Elfandy, J Armenia, F Pederzoli, E Pullman, N Pertega-Gomes, ... Molecular Cancer Research 17 (2), 446-456, 2019 | 52 | 2019 |
| Characterisation of uropathogenic Escherichia coli from children with urinary tract infection in different countries NL Ramos, DTN Dzung, K Stopsack, V Jankó, MR Pourshafie, M Katouli, ... European journal of clinical microbiology & infectious diseases 30, 1587-1593, 2011 | 52 | 2011 |
| Efficacy of PARP inhibition in metastatic castration-resistant prostate cancer is very different with non-BRCA DNA repair alterations: reconstructing prespecified endpoints for … KH Stopsack European urology 79 (4), 442-445, 2021 | 48 | 2021 |
| Statin use is associated with lower risk of PTEN-null and lethal prostate cancer EH Allott, EM Ebot, KH Stopsack, AG Gonzalez-Feliciano, SC Markt, ... Clinical Cancer Research 26 (5), 1086-1093, 2020 | 45 | 2020 |
| Impact of HLA‐mismatch in unrelated donor hematopoietic stem cell transplantation: a meta‐analysis N Kekre, KS Mak, KH Stopsack, M Binder, K Ishii, E Brånvall, CS Cutler American Journal of Hematology 91 (6), 551-555, 2016 | 45 | 2016 |
| The association of diabetes with risk of prostate cancer defined by clinical and molecular features X Feng, M Song, MA Preston, W Ma, Y Hu, CH Pernar, KH Stopsack, ... British Journal of Cancer 123 (4), 657-665, 2020 | 41 | 2020 |
| Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research LM Hurwitz, I Agalliu, D Albanes, KH Barry, SI Berndt, Q Cai, C Chen, ... JNCI: Journal of the National Cancer Institute 113 (6), 727-734, 2021 | 39 | 2021 |
| A prospective study of the association between physical activity and risk of prostate cancer defined by clinical features and TMPRSS2: ERG CH Pernar, EM Ebot, A Pettersson, RE Graff, F Giunchi, TU Ahearn, ... European urology 76 (1), 33-40, 2019 | 39 | 2019 |
| Differences in prostate cancer genomes by self-reported race: contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors KH Stopsack, S Nandakumar, K Arora, B Nguyen, SE Vasselman, B Nweji, ... Clinical Cancer Research 28 (2), 318-326, 2022 | 31 | 2022 |
Lorelei MucciHarvard TH Chan School of Public HealthVerified email at hsph.harvard.edu
